Cost-effectiveness of diagnostic tests for threatened preterm labor in singleton pregnancy in France

Table 3 Cost and effectiveness of seven diagnostic strategies for threatened preterm labor at 24–34 weeks gestational age

Strategies in order of decreasing cost effectiveness	Cost per mother–child, €	Neonatal serious adverse events	ICER^a, €
S₇: CL < 15 mm or CL [16–30 mm] and qualitative fFN	3237	0.0233	–
S₃: Quantitative fFN	4344	0.0256	481,304 (dominated)
S₂: Qualitative fFN	4385	0.0260	425,034 (dominated)
S_ref: CL < 25 mm	4400	0.0262	401,034 (dominated)
S₄: IL-6 cervical	4415	0.0264	380,000 (dominated)
S₅: Combination CL < 18 mm, RANTES plasma, IL-10 plasma	4431	0.0266	361,818 (dominated)
S₆: CL < 15 mm	4718	0.0275	352,619 (dominated)

CL cervical length, fFN fetal fibronectin, IL interleukin
^a Incremental cost-effectiveness ratio expressed in terms of cost per additional serious adverse event. For example, the ICER 481,304 € should be interpreted as following: S₃ is associated to an added cost of 481,304 € per additional neonatal adverse event compared to S₇

ISSN: 1478-7547